An analysis of seven published market forecasts, with commentary from three MDx CRO regulatory specialists.
How this analysis was produced
This article compares seven independently published forecasts of the global medical device market, all issued or updated between January and July 2026. Figures are reproduced as published by each firm, with the source named in every case. No attempt has been made to reconcile them into a single number, because (as the analysis below sets out) the differences are methodological rather than arithmetical.
The commentary is provided by MDx CRO specialists working in regulatory affairs, clinical research, in vitro diagnostics, usability engineering and FDA strategy. Each was asked a single question within their own field.
The number nobody agrees on
If you search for the size of the global medical device market, you will find a confident figure. Search again and you will find a different one. Both will be presented without hedging, and both will be sourced from a reputable market research firm.
Here is what seven firms published for the same market, in the same year:
| Source | Global market, 2026 | CAGR | North America share |
| Fortune Business Insights | USD 604.99bn | 6.90% | 38.1% (2025) |
| Custom Market Insights | USD 621bn | 7.1% | 42% (2025) |
| Towards Healthcare | USD 623.37bn | 6.34% | 40% (2025) |
| Precedence Research | USD 719.61bn | 5.94% | Largest region |
| Future Market Insights | USD 719.63bn | 6.0% | Not stated |
| Mordor Intelligence (Medical Device Technologies) | USD 0.73tn | 6.99% | 45.3% (2025) |
| Coherent Market Insights | USD 735.12bn | 7.3% | 40.4% |
Figures as published by each firm, 2026 editions. Compiled by MDx CRO, August 2026.
The spread is roughly USD 130 billion, or about 21% between the lowest and highest estimate of the same market in the same year. North America’s share ranges from 38.1% to 45.3% depending on who is counting. These are not rounding differences.
The explanation is methodological, and it starts further upstream than most readers expect, with the two inputs that every model is built from.
“From my experience, the difference starts with two variables that look simple but are not: volume and price. Units shipped, sold, installed and actually consumed are related, but they do not necessarily match. Prices also vary significantly by product reference, customer, country and manufacturer, while discounts, rebates or bonuses are often negotiated across a wider product bundle rather than assigned to one item. I would trust the forecast that is most transparent about what it includes, where in the sales chain it measures value, how it calculates volumes and average prices, and which data sources and currency assumptions it uses. The most useful figure is the one whose assumptions best match the manufacturer’s own market.”
David Tomé | President, MDx CRO
Two further definitional choices widen the gap. The largest is scope: some firms count in vitro diagnostics within the medical device market while others treat IVDs as an adjacent category, a decision that moves the total by more than a hundred billion dollars on its own. The second is the treatment of capital equipment, consumables and service contracts, which some models consolidate into a single device revenue line and others report separately.
None of this makes the forecasts wrong. It makes them non-comparable. The practical consequence is that a manufacturer quoting a market size in an investor deck or a partnering discussion should be able to say which definition it is using, and why that definition matches its own commercial reality.
What every forecast does agree on
Beneath the disagreement about magnitude, the direction of travel is remarkably consistent. Every model in the comparison forecasts sustained mid-to-high single-digit annual growth through the early 2030s, and every one attributes it to the same underlying drivers: population ageing, rising chronic disease prevalence, the migration of care from hospitals into ambulatory and home settings, and the absorption of software and artificial intelligence into conventional device categories.
The regional picture is also consistent in shape if not in scale. North America remains the largest single market on every model. Asia-Pacific carries the highest forecast growth rate on every model, with China frequently singled out as the fastest-growing national market. Europe sits between the two, large and stable rather than fast-growing, a position shaped as much by regulatory transition costs as by demand.
The composition of the European market, its principal hubs and the companies operating within it are covered separately in our overview of MedTech companies in Europe.
Diagnostics: the segment everyone sizes differently
In vitro diagnostics is the clearest illustration of the definitional problem. Across the same set of 2026 forecasts, IVDs are reported as holding roughly 16%, 21.2% and 24.4% of the total device market depending on the source, a range of eight percentage points on a market measured in hundreds of billions.
The variance is not carelessness. It reflects a genuine question about where the boundary of an in vitro diagnostic sits: whether laboratory instrumentation is counted alongside assays, whether laboratory-developed tests are included, and whether companion diagnostics are counted within IVDs or within oncology. Each of those choices is defensible, and each produces a different number.
What is not in dispute is that diagnostics is growing while operating under the most demanding evidence regime it has ever faced. Under the EU IVDR, the proportion of products requiring Notified Body involvement rose from a small minority under the previous directive to the large majority, a shift that changed the cost base of the entire segment rather than a subset of it. We examine the longer-term implications in the future of in vitro diagnostics.
That change is not only a matter of producing more documentation. It requires manufacturers to plan evidence as a connected lifecycle system. “A robust IVDR Performance Evaluation Plan should be built as a single, integrated lifecycle framework that connects Scientific Validity, Analytical Performance and Clinical Performance back to the device’s intended purpose, claims, risks and applicable GSPRs.”
Catarina Sepúlveda | Regulatory Director, IVD Team, MDx CRO
Devices: where market growth meets market-access friction
The device segment outside diagnostics is where the growth forecasts translate most directly into regulatory workload. One 2026 model puts Class II devices at 56.3% of the market by revenue, the moderate-risk band where general controls alone are insufficient and special controls apply. Growth concentrated in that band means growth concentrated in exactly the category that requires conformity assessment, clinical evidence and active post-market surveillance.
There is a second-order effect that market models do not capture at all. When a market grows, it grows partly through entrants from outside the region. A manufacturer headquartered in the United States, China, Japan or Israel that wants to sell into the European Union needs an authorised representative established in the Union, and since Brexit a separate responsible person for the United Kingdom. The growth curve is, in part, a curve of foreign manufacturers acquiring European regulatory infrastructure they did not previously need.
That obligation is frequently discovered late, at the point where a commercial launch date is already fixed. Our EU and UK representative services exist precisely for that moment.
AI-enabled and software devices: the fastest-growing, least settled segment
Every forecast in the comparison identifies artificial intelligence as the highest-growth technology category, and the numbers attached to it are extraordinary. One 2026 model places AI-based devices at 33.2% of the technology category by share. Another projects the AI-in-medical-devices market growing from roughly USD 32bn in 2025 to close to USD 886bn by 2034, implying a compound annual growth rate above 44%.
Forecasts of that magnitude should be read with care. They describe a technology that is being absorbed into existing device categories rather than forming a separate market, which makes double-counting almost unavoidable. They also assume a regulatory environment that does not yet exist in stable form.
In the European Union, an AI-enabled medical device now sits at the intersection of the MDR or IVDR and the EU AI Act, with most such devices falling into the high-risk classification and inheriting a second set of conformity obligations on top of the first. In the United States, the FDA continues to refine how it evaluates software-driven and adaptive devices, often requiring evidence that is difficult to generate inside conventional development timelines. Neither framework is finished, and neither is priced into a 44% growth rate.
The United States: growth against a moving regulatory floor
North America is the largest market on every model in the comparison, and the United States accounts for the overwhelming majority of it. It is also the market where the regulatory baseline has shifted most recently.
The FDA’s Quality Management System Regulation took effect on 2 February 2026, replacing the previous Quality System Regulation and incorporating ISO 13485:2016 by reference into 21 CFR Part 820. For manufacturers already certified to ISO 13485 the change reduces duplication; for those who built their quality system to the old Part 820 alone, it is a structural remediation project rather than a documentation update.
In parallel, the FDA proposed in November 2025 to reclassify nucleic acid-based oncology companion diagnostics from Class III, requiring premarket approval, to Class II with a 510(k) pathway. If finalised, it would materially reduce the cost of entry for a category that has historically been among the most expensive to bring to market. It has not been finalised, and programmes currently in development are still being planned on the premarket approval assumption.
What the forecasts do not price in
Market models forecast demand, but they do not forecast the cost of being allowed to meet it.
Not one of the seven forecasts in this comparison incorporates the time or expenditure required to generate clinical evidence, and for a moderate- or high-risk device that is frequently the single largest determinant of whether a product reaches the market inside its commercial window. A device with confirmed demand and confirmed reimbursement can still miss its launch by two years because the clinical investigation was scoped after the development plan rather than alongside it. Our overview of clinical development for medical devices sets out how that sequencing works when it works well.
In multi-centre IVD performance studies, that gap becomes operational very quickly. “In practice, specimen availability and quality are usually the primary recruitment bottlenecks, site variability is the main monitoring challenge, and multi-jurisdiction ethics approvals are the leading startup delay.”
Kirsty Macleod | Head of Clinical Research, MDx CRO
Industry sentiment data points in the same direction. In Deloitte’s 2026 Life Sciences Outlook, based on a survey of 280 C-suite executives across biopharma and medtech, more than 75% of respondents expressed confidence in their own organisation’s financial prospects while only 41% were optimistic about the wider economy, and regulatory shifts ranked alongside geopolitical tension and pricing pressure among the trends most likely to affect strategy. Confidence in the demand curve is not the same as confidence in the path to it.
The medical device market entering 2027: a strategic assessment
Read as a position rather than a projection, the sector entering 2027 looks like this from a regulatory and clinical standpoint.
| Strengths | Weaknesses |
| Demand fundamentals are structural, not cyclical, ageing populations and chronic disease prevalence are not sensitive to economic conditions. Every independent forecast agrees on direction and on mid-to-high single-digit growth. Regulatory frameworks in the EU and US are now largely defined rather than in flux, giving planners a stable baseline. | No agreed definition of the market itself, making benchmarking and investor communication unreliable. Evidence generation costs have risen faster than device margins, particularly under the IVDR. Notified Body capacity remains a throughput constraint on European market entry. |
| Opportunities | Threats |
| The proposed EU MDR and IVDR targeted revision could reduce administrative burden and lower fees for SMEs. FDA reclassification of oncology companion diagnostics would cut the cost of entry for a historically expensive category. Asia-Pacific growth rates exceed those of established markets, and regulatory convergence is improving. | AI regulation is arriving faster than AI evidence standards, creating compliance exposure in the fastest-growing segment. Supply chain and geopolitical volatility now rank among executives’ top strategic concerns. Divergence between EU, UK and US requirements is increasing the fixed cost of multi-market presence. |
The regulatory simplification measures referenced above are analysed in detail in our briefing on the MDR and IVDR targeted revision.
What this means for manufacturers
The useful conclusion is not a number. It is that the market is growing reliably enough to plan against, and that the constraint on capturing that growth is almost never demand.
Three practical positions follow. Quote market size with its definition attached, and choose the forecast whose assumptions most closely match your own product, channel and geography rather than the one with the largest headline. Treat regulatory and clinical evidence planning as a determinant of launch date rather than a downstream activity, because it usually is. And assume, when entering a new region, that the market-access infrastructure, authorised representation, conformity assessment, local evidence expectations, takes longer to assemble than the commercial plan allows for.
MDx CRO supports medical device and IVD manufacturers across regulatory strategy, clinical evidence generation and market access in the EU, UK and US. Talk to our team about your development programme.
Frequently asked questions about medical device industry trends
The seven forecasts reviewed by MDx CRO place the global medical device market between USD 604.99 billion and USD 735.12 billion in 2026. This range should not be treated as a single reconciled estimate because the reports use different definitions, scopes and valuation methods. Any market-size figure should therefore be accompanied by its source and underlying definition.
Medical device market forecasts disagree because research firms do not always measure the same products, transactions or stages of the sales chain. David Tomé highlights the distinction between units shipped, sold, installed and consumed, as well as variations in pricing by product, customer, country and commercial agreement. Scope also matters, particularly whether IVDs, consumables, capital equipment and service contracts are included.
Commercial growth does not change the IVDR requirement for continuous performance evaluation. Catarina Sepúlveda explains that scientific validity, analytical performance and clinical performance should be planned as connected parts of a lifecycle evidence framework. Manufacturers therefore need to align their intended purpose, claims, risks, applicable GSPRs, acceptance criteria, studies and post-market updates from the beginning of development.
Market forecasts usually measure demand, revenue and growth rather than the device-specific time and cost required to generate clinical evidence. Kirsty Macleod’s experience with multi-centre IVD performance studies shows how specimen availability and quality, site variability and multi-jurisdiction ethics approvals can become material constraints. These operational factors can delay market entry even when commercial demand is strong.
